EP2968573A1 - Solution thérapeutique liquide exempte de colorant - Google Patents

Solution thérapeutique liquide exempte de colorant

Info

Publication number
EP2968573A1
EP2968573A1 EP14714047.9A EP14714047A EP2968573A1 EP 2968573 A1 EP2968573 A1 EP 2968573A1 EP 14714047 A EP14714047 A EP 14714047A EP 2968573 A1 EP2968573 A1 EP 2968573A1
Authority
EP
European Patent Office
Prior art keywords
weight
liquid composition
composition
liquid
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14714047.9A
Other languages
German (de)
English (en)
Inventor
Mahesh Sudhakar BHARATI
Houphouet Hyacinthe YARABE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Consumer Healthcare SARL
Novartis Consumer Health Inc
Original Assignee
Novartis Healthcare Pvt Ltd
Novartis Consumer Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Healthcare Pvt Ltd, Novartis Consumer Health Inc filed Critical Novartis Healthcare Pvt Ltd
Priority claimed from PCT/US2014/021590 external-priority patent/WO2014149939A1/fr
Publication of EP2968573A1 publication Critical patent/EP2968573A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Definitions

  • the present invention provides a dye-free therapeutic formulation that is- present as a single phase at room temperature.
  • Atients having difficulty swal lowing therapeutic compositions in tablet and/or capsule form may find it preferable to ingest the therapeutic compositions in a liquid dosage form where the therapeuiic composition is present in a liquid carrier system.
  • the liquid composition is then delivered to the patient in a measured form (e.g. in a prepackaged single dose package, disposable container, or in a bottle from which the patient or care giver can measure the appropriate dosage).
  • Formulating liquid therapeuiic compositions is ehallenging in terms of selection of suitable liquid carriers.
  • suitable liquid carriers For example, acetaminophen crystallizes in liquid products when it is stored at decreased temperature. Furthermore;, acetaminophen degrades at elevated temperatures and produces discolored liquid compositions. These instabilities, imer alia, decrease shelf life of liquid therapeutic compositions and lead t the need to set shorter expiration dates as compared to other types of dosage forms.
  • Solutions to these problems can include selecting -solvents that are not suitable tor many people (e.g. alcohol) and the addition coloring materials, such as dyes, to mask the color of liquid compositions containing degradable active ingredients.
  • many liquid formulations suspend active ingredients in a. "two-phase" ' composition ' which must he shaken prior to administering a dosage to a patient.
  • These two phase systems generally appear cloudy Or opaque in nature.
  • Providing a clear, essentiall clear or translucent solution may also provide a benefit, in administering the same to patients that are not comfortable ingesting cloudy, opaque or dye-containing medicines.
  • the present invention relates to liquid pharmaceutical compositions suitable for oral administration.
  • the present Inventors have discovered that the liquid therapeutic compositions of the present invention are present in a single phase (e.g. solutions) at room temperature and do not require the addition of coloring material (e.g. dyes) to mask the color of degraded active ingredients (e.g. the actives are stable within the compositions at various storage conditions and durations).
  • the formulations exhibit improved stability and can be present as translucent, and preferably clear solutions,
  • a liquid composition in one embodiment, includes an active pharmaceutic.*, ingredient dissolved in a liquid carrier system.
  • the liquid carrier includes a solvent syst en v including polyethylene glycol and a co-solvent selected tram the group consisting, of propylene glycol glycerin, and a sugar alcohol.
  • Other co-solvents may include others known to be suitable to one skilled In the art.
  • the composition can be essentially dye free and present as single-phase at room temperature.
  • the present invention provides a method of treating a cold -and/or Cold-like syniptonis by administering to an individual a safe and effective amount of the liquid composition described above.
  • the present inventors have -discovered- polyethylene glycol when melted and mixed with a co-solvent selected from the group consisting of propylene glycol, glycerine, and a sugar alcohol, or the like, serves to solubilize the pharmaceutical compounds and inhibit crystallization at o below room temperature and prevent degradation at or above room temperature.
  • a co-solvent selected from the group consisting of propylene glycol, glycerine, and a sugar alcohol, or the like.
  • an active component refers to either a single species of compound or a mixture of ' such species unless the context indicates otherwise.
  • liquid carrier' refers to an solvent system for the acti ve ingredients.
  • the solvent system includes polyethylene glycol and a co-solvent selected from the group consisting of: propylene glycol, glycerin, and a sugar alcohol (or suitable other co-solvents). These compositions are preferably essentially free of, or most preferably -completely- free of, ethanoL
  • liquid carrier system may optionally contained water, for example up to 50 wt% of the composition,
  • essential free of dye means that; the liquid composition does not require a colorin agent to be added to impart color for masking -unpleasant color of degraded active.
  • additional excipients which may impart color include flavorants (e.g. liquid sugar) or other materials which impart flavor to the composition or non-dye containing excipients thai have color.
  • single phase is herein understood to mean that the liquid compositions of the present invention are not suspensions at room temperature.
  • the liquid co p sitions ' ) of the present invention is a solution at room temperature where the active ingredient(s) remain dissolved in the liquid carrier system.
  • the l iquid compositions of the present invention are preferably clear and/or translucent.
  • Ranges given in the specification ar inclusive of either end of the specified range. Re ferenee throughout the specification to ''one embodiment, " “another .embodiment,” “an embodiment, “ ' “ 'some embodiments ' and so forth, means that a particular element (e.g., feature, structure, property, and/or characteristic) described in connection with the embodiment is included in at least one embodiment described herein, and may or may not be present in other embodiments. In addition, it is to be Understood thai the described element(s) may be combined in any suitable manner in the various embodiments.
  • the active .pharmaceutical ingredient of the liquid compositions of the present invention is selected from the ' .group consisting of: acetaminophen, guaifenesin, pseudoephedrine ifC!,
  • the. active pharmaceutical ingredient comprises, or is solely, acetaminophen.
  • acetaminophen if acetaminophen is present it may be present in am unts of up to about 3,5 wt% of the formulation. Preferably acetaminophen is present in amounts of about 1.6% to about 3.5% of the formulation. Most preferably acetaminophen is present in an amount of about.3.2% of the formulation.
  • guaifenesin is present it may be present in amounts of up to about 300 milligrams per S ml of the excipient ' base.
  • guaifenesin is present i n. amounts of about 10 to about 300 milligrams per 5 mi of the excipient base.
  • guaifenesin is present ' in amounts of about 100 ta about 200 milligrams per unit dose of the excipient base.
  • pseudoephedrtne HCl may be present in amounts of betwee about 10 and about 60 milligrams per unit dose of the excipient base.
  • pseudoephedrine is present in amounts of about - 30 to about 60 milligrams per unit dose of the excipient base.
  • dextromethophan is present in amounts of between about 5 and about 30 milligrams per unit, dose of the excipient base.
  • dextromethorphan is present in amounts of about 10 to about 30 milligrams er unit dose of the excipient base.
  • ibuprofen is present it may be present in amounts of from about 50 to about 200 milligrams per 5 ml of the excipient base. Preferably, .ibuprofen is present in amounts of about 100 to about 200 milligrams per unit dose of the excipient base.
  • the liquid carrier system of the liquid compositions of the present invention includes a solvent system and also optionally, but preferably, includes water.
  • the solvent system includes polyethylene glycol and a co-solvent selected from the group consisting of propylene glycol, glycerin, and a sugar alcohol (e.g. sorbitol, mahitol, xyfitoi, etc. which ac as sol vents, sorbitol being preferred), or similar co-solvents.
  • the co-solvent most preferably comprises propylene glycol and glycerin. However, solely propylene glycol, glycerin, or sugar alcohol can make up the entirety of the eo-solvent In.
  • the co-solvent preferably comprises all three propylene glycol, glycerin, and sugar alcohol . Without being bound by a mechanism of intended action it is believed that propylene glycol concentration within the co-solvent can. be reduced by increasing the concentration of the other co-solvents, and vice versa.
  • liquid carrier components and ranges which provide for dissolution and stabilization of the active ingredients such that the composition is present as single-phase at room temperature.
  • the liquid carrier In 100 ml of the liquid carrier the following components are present: (i) about 5 to about 2D grams of polyethylene glycol having a molecular weight of about 1000 to about 2000 r
  • the weight ratio of polyethylene glycol to propylene glycol is between about 3 : 1. and about 8: 1.
  • liquid composition will include:
  • ⁇ iyj Sorbitol solution 2% -20%, particularly 1.0 to 15% (e.g., 13%);
  • purified water may optionally be present in varying amounts and preferably makes up less than 50 wt % (for example between 30 to 40 wt%) of the liquid carrier system. m another embodiment, the water is preferably present in an amount not less than about 5- 10 wt% of the composition.
  • the polyethylene glycols, useful in the practice of the present invention include those havi ng an average molecular weight of about 1000 to about 2.000-
  • the -polyethylene glycol has an average molecular weight of about 1400 to about 1600,
  • the polyethylene glycol used n the practice of the present invention has an average molecular weight of about 1450.
  • the use of mixtures of such polyethy lene glycols is further within the scope of the present invention.
  • the polyethylene glycol component may be present in amount of about 5 to about 20 grams, preferably about 15 to about 20 grams, per 100 milliliters of the liquid excipient base.
  • the polyethylene glycol in. the specific examples is Polyethylene Glycol 1450 N.F.
  • This polyethylene glycol having a molecular weight of 1450 can be obtained from a number of suppliers. For instance, it is sold b Union Carbide Chemicals and Plastic Company, Inc. of Danbury, onn, as CARBQWA ® 1450® and by Dow Chemical Company of Midland, Mich, as Dow Pe!yglycol E1450.
  • the propylene -glycol is preferabl a non-toxic grade of the compound and be
  • Such phar aceutically acceptable grades of propylen glycol are commercially available fern, for example. The Dow Chemical Company.
  • polyethy lene glycol when melted and mixed with a co-solvent selected from the group consisting of: propylene glycol, glyeerine s and a sugar alcohol, serves to solubilize the pharmaceutical compounds and inhibit crystallization and degradation over time and/Or at, below, or above, room temperature (about .20-25 * C).
  • a co-solvent selected from the group consisting of: propylene glycol, glyeerine s and a sugar alcohol
  • the formulations preferably remain suitable for any particular climate zone (e.g. 1- lV), more preferably a combination of climate zones, and most preferably all climate zones, Further it is an aspect of the present invention that the compositions remain as a single phase ..-solution fo extended storage periods at depressed, norma! and elevated temperatures.
  • the liquid composition is preferably present: as a single-phase after 6-raoirths of storage at about 3 "C; as a single-phase after 6-months of storage: at about 25 "C; and/or as a single-phase after 6-months of storage at about 40 °C.
  • ddiiive Agents as a single-phase after 6-raoirths of storage at about 3 "C; as a single-phase after 6-months of storage: at about 25 "C; and/or as a single-phase after 6-months of storage at about 40 °C.
  • the liquid composition will further comprises an additive selected from the group consisting of: a fiavorant, a preservative, a pH buffer, and combinations thereof.
  • a fiavorant such as orange, grape, vanilla, cherry, cranberry . , peppermint, spearmint, anise, blueberry raspberry, banana, chocolate, honey, caramel, citrus, strawberry, lemon, and lime.
  • flavorants include cherry or grape.
  • the liquid composition comprises a sweetener including liquid sugar.
  • the liquid composition comprises a pH buffer (e.g. a buffering agent) in an amount sufficient to maintain the pH of the liquid composition at a pH of less than 7.0 and more preferably in a range of between about 3.0 and .6.9, tor example between 3.5 and 6.7, for example between 4 and 6.3 (e.g. between about 5.0 and 6.1 , for example 5.9, 6.0, or 6.1 ).
  • a pH buffer e.g. a buffering agent
  • suitable buffers includes- sodium citrate and citric acid.
  • th liquid composition comprises a preservative agent.
  • preservatives useful in the present invention include but are. not limited to sodium benzoate. sorbates, such as potaSfSium sorhate, benzald ionium chloride and patabens (such as methyl, ethyl, propyl, and bitty! p-hydroxybenzoic acid esters). Preservatives listed above are exemplary, but each preservative must be evaluated on an experimental basis based upon what is known in the art to one of ordinary skill in the art in each formulation to -assure compatibility and efficacy of the preservative.
  • the preservative is a paraben such as methyl paraben, ethy l paraben, propyl paraben, and/or butyl paraben.
  • Preservatives are generally present irs amounts of up to about one gram per 1O0 nil :of the pharmaceutical composition, Preferably- he preservatives are present in amounts in the range of from about 0. 1 w/v to about 0.4 w/v of the eomposiiion.
  • the preservative methy l paraben and/or propyl paraben -could be present in the range of about 0.1. w/v to about ⁇ .2 w/v of the composition, for example.
  • .methyl paraben could be present in a concentration of about 0. I S w/ -while propyl paraben could be present- In a concentration .of about-0.02%.
  • the liquid composition is essentially free of antioxidants (e.g. less than about I vvt%, for example about 0, wt%). Oxidation of active ingredients is a common route to degradation of the active ingredient. In the present invention, stability of the active ingredients is imparted by the described selection of components of liquid carrier system which does not require the presence of an antioxidant.
  • the liquid compositions of the present invention are preferred for use in treating o reducing cold or cold-like symptoms.
  • a person suffering from cold or cold-iike symptoms ma find relief by orally ingesting a safe and effective amount of the liquid compositions as described above.
  • the safe and -effective amount of liquid composition is dependent upon the concentration of the therapeutic components present in the liquid compositions, the amount ingested, and the patient.
  • the .-safe and effective amount of liquid composition is in a range between about 3.75 ml to 30 ml of the liquid composition.
  • the patient receiving a dosage of the composition is less than 12 years old, for example less than 5 years old (e.g. Jess than 2 or 1 years old).
  • the safe and effective amount of liquid composition is measured in drops from a dropper, spoon, or syringe and may be les than 5 ml (e.g. 1 - 10 drops or 1 -S ml).
  • a safe and effective dosage amount i as follows:
  • ⁇ preferred liquid compositions is essentially free of ethanol (eg. less than 2 wt-% ethanoi ) and in most preferred embodiments less thaii l wt% (e.g. no ethanol of 0 wWi ethanol).
  • exemplary Liquid Com&osit tn e.g. less than 2 wt-% ethanoi ) and in most preferred embodiments less thaii l wt% (e.g. no ethanol of 0 wWi ethanol).
  • This exemplary liquid forrnulariou includes:
  • Acetaminophen about 1.6-3.5% by weight (e.g. about 3.2% by weight)
  • the methods usee to prepare the liquid compositions of the present invention are not particularly limited. However, in a preferred embodiment the following steps can be used, -to prepare a flavored liquid composition ⁇ including acetaminophen in a liquid carrier system comprising water and a solvent, wherein the liquid composition is present as a single phase at room temperature.
  • Temperature is then preferably adjusted to 50-55°C and edetate di sodium, sodium citrate, citric acid, polyethylene glycol, are weighed and introduced 1.0 the vessel.
  • Flavor e.g. grape, etc. is measured and added.
  • a method of preparing a liquid formulation preferably containing acetaminophen and, optionally, one or more other active ingredients is provided wherein the liquid formulation is present as a single phase at room temperature.
  • the method includes follo ing steps: (a) solubltzmg sweetening agents in an aqueous vehicle (b) soluhlizmg of preservative in propylene glycol (c) adding PEG and addiuonai solvents selected fiom the group consisting of glycerin, sorbitol, and additional PG .(d) adding and dissolving active pharmaceutical ingredient, (e) adjusting the volume to a standard volume by adding additional sweeteners, co-solvent, flavoring- system, and/or water.
  • the temperature of formulation is about 130 cfcl0° F. (e.g. 1. 1 ⁇ 5° F).
  • Example 1 includes two separate batches (A and B) prepared at a pH of about 6,0, Both batches provided the following observations at the given stability conditions in sealed containers:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une composition liquide. La composition comprend au moins un principe pharmaceutique actif dissous dans un système de support liquide. Le support liquide comprend du polyéthylène glycol et un cosolvant choisi dans le groupe consistant en : propylène glycol, glycérine et un alcool de sucre. La composition est essentiellement exempte de colorant, présente sous la forme d'une monophase à la température ambiante, et contient facultativement de l'eau.
EP14714047.9A 2013-03-15 2014-03-07 Solution thérapeutique liquide exempte de colorant Withdrawn EP2968573A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN765DE2013 2013-03-15
PCT/US2014/021590 WO2014149939A1 (fr) 2013-03-15 2014-03-07 Solution thérapeutique liquide exempte de colorant

Publications (1)

Publication Number Publication Date
EP2968573A1 true EP2968573A1 (fr) 2016-01-20

Family

ID=54258944

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14714047.9A Withdrawn EP2968573A1 (fr) 2013-03-15 2014-03-07 Solution thérapeutique liquide exempte de colorant

Country Status (4)

Country Link
EP (1) EP2968573A1 (fr)
CN (1) CN105263524A (fr)
CA (1) CA2906389A1 (fr)
SG (1) SG11201507369WA (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110115708A (zh) * 2018-02-07 2019-08-13 保瑞药业股份有限公司 乙酰胺酚及曲马多共溶复方止痛口服液

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0714872B2 (ja) * 1990-02-06 1995-02-22 昭和薬品化工株式会社 シロップ剤組成物
US5505961A (en) * 1993-08-05 1996-04-09 R. P. Scherer Corporation Gelatin capsules containing a highly concentrated acetaminophen solution
US5616621A (en) * 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
DE60239752D1 (de) * 2001-10-22 2011-05-26 Taro Pharma Ind Den geschmack verdeckende auslaufsichere formulierung
US20080085892A1 (en) * 2006-08-31 2008-04-10 Sangeetha Kandeepan Liquid dosage form of acetaminophen

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2014149939A1 *

Also Published As

Publication number Publication date
SG11201507369WA (en) 2015-10-29
CA2906389A1 (fr) 2014-09-25
CN105263524A (zh) 2016-01-20

Similar Documents

Publication Publication Date Title
CA2333528C (fr) Sirop a antihistamines stabilise contenant un stabilisant acide aminopolycarboxylique
TW201105334A (en) Topical formulation containing a tetracycline and a method of treating skin infections using the same
CA2567075A1 (fr) Suspension pharmaceutique
JP2006312651A (ja) オキシカルバゼピン含有懸濁剤
WO2014149939A1 (fr) Solution thérapeutique liquide exempte de colorant
WO2014013903A1 (fr) Composition liquide contenant un principe actif à base de taxane, son procédé de fabrication et préparation médicinale liquide
JP4959335B2 (ja) メチルフェニデート溶液および関連する投与および製造方法
EP2968573A1 (fr) Solution thérapeutique liquide exempte de colorant
US20210322345A1 (en) Midodrine hydrochloride oral solution and uses thereof
JP5211677B2 (ja) 内服液剤
JPH0536412B2 (fr)
US20040116528A1 (en) Ketoprofen compositons and methods of making them
US20210213024A1 (en) Liquid compositions of aprepitant
CN107714644B (zh) 口服使用的悬浮液形式的枸橼酸西地那非的药物组合物
WO2024062443A1 (fr) Compositions pharmaceutiques
AU2004203644B2 (en) Pharmaceutical compositions
CN114828829A (zh) 包含布洛芬和去氧肾上腺素的液体组合物
WO2005034910A1 (fr) Compositions pharmaceutiques liquides de sertraline a administration orale
MXPA00005129A (en) Liquid and stable antihistaminic - anti-congestive pharmaceutical compositions
MXPA00011834A (en) A stabilized antihistamine syrup containing aminopolycarboxylic acid as stabilizer
ITMI991780A1 (it) Composizioni liquide orali contenenti citalopram

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151013

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVARTIS CONSUMER HEALTH, INC.

Owner name: NOVARTIS CONSUMER HEALTH S.A.

17Q First examination report despatched

Effective date: 20170220

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20171110